Revolutionizing Global
Biosecurity Markets
Join us in scaling proven UV-C + Ozone technology across $50B+ addressable markets with validated product-market fit and exponential growth trajectory
Massive Market Opportunity
Multiple high-growth verticals with urgent biosecurity needs and proven willingness to pay
Healthcare
HAI prevention, OR sanitation, patient safety compliance
Food Safety
FSMA compliance, contamination prevention, audit readiness
Agriculture
Disease control, biosecurity protocols, livestock protection
Defensible Competitive Moat
Multi-patented technology with regulatory approvals and proven efficacy
IP Protection
- Multi-patented UV-C + Ozone technology
- Proprietary dual-action mechanism
- Trade secrets in manufacturing process
Regulatory Approvals
- NSF International tested & verified
- EPA registered disinfection device
- TÜV SÜD certified, CE marked
Proven Efficacy
- 99.9993% pathogen elimination validated
- Third-party lab testing (NSF, CREM Co)
- Published case studies with ROI data
Operational Excellence
- Made in USA (ISO 9001:2015 facility)
- 6-10 second treatment cycle
- Minimal maintenance, 10,000 hour lamp life
Scalable Growth Strategy
Clear path to market dominance with proven go-to-market playbook
Phase 1: Market Penetration
Current - 18 months
- Expand healthcare footprint in top 50 hospital systems
- Scale food processing partnerships with Fortune 500 manufacturers
- Build distribution network across North America
Phase 2: Product Line Extension
18-36 months
- Launch hand sanitization and surface disinfection units
- Develop IoT-enabled monitoring and compliance platform
- Introduce subscription-based service model
Phase 3: Global Expansion
36-60 months
- Enter European and Asian markets via strategic partnerships
- Establish regional manufacturing and service centers
- Pursue strategic acquisitions in complementary technologies
Investment Highlights
Strong unit economics with clear path to profitability
Premium pricing with low COGS
Rapid ROI drives adoption
Sticky product with recurring revenue
Ready to Learn More?
Request our comprehensive investor deck with detailed financials, market analysis, and growth projections
For inquiries: info@patho3gen.com | 727-300-1069